Tag: rimegepant

1. Rimegepant significantly reduced the mean number of migraine days per month between the last 4 weeks of treatment and the observation period compared to placebo (-4.3 days vs. -3.5 days). 2. Patients in both groups were equally likely to have an adverse event and most events were mild-moderate in...
1. Rimegepant significantly reduced the mean number of migraine days per month between the last 4 weeks of treatment and the observation period compared to placebo (-4.3 days vs. -3.5 days). 2. Patients in both groups were equally likely to have an adverse event and most events were mild-moderate in...
1. Patients with migraine treated with rimegepant during an acute event had resolution of pain and their most bothersome symptoms 2 hours after onset more frequently than patients treated with placebo. 2. Incidence of adverse events were similar for patients treated with either rimegepant or placebo. Evidence Rating Level: 1 (Excellent)...
1. Patients with migraine treated with rimegepant during an acute event had resolution of pain and their most bothersome symptoms 2 hours after onset more frequently than patients treated with placebo. 2. Incidence of adverse events were similar for patients treated with either rimegepant or placebo. Evidence Rating Level: 1 (Excellent)...